Oxidated derivatives of triazolylpurines useful as ligands of the adenosine A2A receptor and their use as medicaments
US9133197B2 · kind B2 · utility
3Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 18, 2010 |
| Grant date | Sep 15, 2015 |
| Priority date | — |
| Expiry date | Mar 12, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to new triazolyl purine derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders or cerebral ischaemia for which inhibition of adenosine A2A receptor will result at improving the health state of a patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.